<DOC>
	<DOCNO>NCT01130831</DOCNO>
	<brief_summary>To assess percentage patient lanthanum carbonate , achieve Kidney Disease Outcome Quality Initiative ( KDOQI ) guideline suggest value serum phosphorous patient previously treat calcium-based phosphate binder therapy .</brief_summary>
	<brief_title>Effect Lanthanum Carbonate Patients Previously Treated With Calcium-based Phosphate Binder Therapy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients meet criterion list may include study : 1 . Patients age 18 year 2 . Patients ESRD haemodialysis willing able provide write informed consent . 3 . Patients : Lanthanum carbonate monotherapy ≥1 month Lanthanum carbonate monotherapy ≤3 month Calciumbased monotherapy ≥3 month immediately prior lanthanum carbonate therapy . 4 . Values record medical record detail serum phosphorous , serum calciumphosphorus product , iPTH , medication ≤6 month prior commence lanthanum carbonate therapy whilst calciumbased monotherapy . Patients exclude study follow criterion meet screening : 1 . Known suspected intolerance hypersensitivity lanthanum , state ingredient 2 . Patients know hypophosphatemia ( phosphate level lower level normal ) 3 . Patients severe hepatic impairment 4 . Patients requirement calcium supplementation reason CKD 5 . Pregnant lactate woman woman plan become pregnant next 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>